SCN5A and long QT syndrome 3: Our recent experimental results (8) show that DIII-VSD dynamics significantly regulate mexiletine blockade of NaV1.5, and the differential response of long QT syndrome type 3 (LQT3) carriers to mexiletine is due, in large part, to mutation-specific VSD dynamics.